1 discusses our recent article published in The BMJ. 2 We are sad dened that Howard, a member of the ACT NoW Trial Steering Committee, is critical of the trial and welcome the opportunity to respond. We have some concern that therapists unfamiliar with the original pub lications 2-4 or with randomized trial metho dology may be misled by the debate. Leff and Howard focus on secondary questions and do not acknowledge that the first imperative for an evidence base is to es tablish whether an intervention is effective.
Leff and Howard raise three concerns. First, they query the control over constitu ents of both interventions. Speech and lan guage therapy (SLT) is, as they acknowledge, a complex intervention that varies according to an individual's needs. In the ACT NoW trial, therapists agreed upon a range of SLT activities and tailored their intervention within that range to the perceived needs of each patient. A trial of a 'onesizefits all' therapy would have attracted justifiable criticism. For the control group, 'visitors' were trained and monitored to ensure that they did not deliver anything considered as therapy; they certainly did not provide con versation therapy-a promising technique that merits further clinical research.
Second, the dose of SLT was queried. Leff and Howard suggest the naive view that 'therapy' constitutes only direct contact, and dismiss the five other components selected by participating therapists. Standard NHS care is stated as involving 8 h of SLT-less than the 9 h of 'direct contact' and the 18 h of broad intervention delivered in ACT NoW. Notably, these times were shorter than the total offered, reflecting choices made by service users. The Cochrane review of SLT for aphasia warns of patient dropout from high intensity interventions.
Clarification of conclusions from the ACT NoW trial
5 Service com missioners are unlikely to agree that an average of 18 h is homeopathic. Our findings have relevance to current service provision whereas commissioners may not be able to respond to a trial delivering 100 h of therapy.
Finally, the issue of 'absence of evidence' versus 'evidence of absence' was raised. Leff and Howard are correct: evidence showing absence of effect cannot be inferred from a statistical significance test. They fail to note, however, that our inference was correctly based on the confidence interval. The BMJ continues to exercise stringent statistical re fereeing of articles prior to acceptance.
We have been painstaking in drawing appropriate conclusions from the evidence provided by ACT NoW, specifically that this form of SLT offered at this intensity and duration at this time after stroke was no more effective than attention control for enhancing functional communication or any other outcome, including patients' and carers' own perceptions of effect. 3, 4 We do not extrapolate from our evidence to con clude that SLT is no better than inactivity, or that it would be no better than attention control if given at different times, durations or intensity.
